Pfizer Inc. (NYSE:PFE) saw a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 46,551,071 shares, a decline of 7.5% from the October 15th total of 50,351,438 shares. Approximately 0.8% of the company’s shares are sold short. Based on an average trading volume of 26,087,863 shares, the short-interest ratio is currently 1.8 days.

Shares of NYSE PFE opened at $42.91 on Thursday. Pfizer has a 52-week low of $33.20 and a 52-week high of $45.81. The firm has a market cap of $262.58 billion, a PE ratio of 16.19, a P/E/G ratio of 2.22 and a beta of 0.88. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.15.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.03. Pfizer had a net margin of 44.63% and a return on equity of 25.26%. The company had revenue of $13.30 billion during the quarter, compared to analysts’ expectations of $13.53 billion. During the same period in the previous year, the company earned $0.67 EPS. The business’s quarterly revenue was up 1.0% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer will post 3 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Friday, November 9th will be paid a dividend of $0.34 per share. The ex-dividend date is Thursday, November 8th. This represents a $1.36 annualized dividend and a dividend yield of 3.17%. Pfizer’s dividend payout ratio is presently 51.32%.

PFE has been the subject of several analyst reports. Cantor Fitzgerald reiterated a “buy” rating and issued a $53.00 price target on shares of Pfizer in a report on Wednesday, October 17th. Morgan Stanley set a $45.00 price target on Pfizer and gave the company a “buy” rating in a report on Thursday, September 13th. Barclays reiterated a “neutral” rating and issued a $40.00 price target on shares of Pfizer in a report on Wednesday, September 26th. BMO Capital Markets reiterated a “buy” rating and issued a $44.00 price target on shares of Pfizer in a report on Monday, August 27th. Finally, Credit Suisse Group set a $40.00 price target on Pfizer and gave the company a “hold” rating in a report on Sunday, October 14th. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eight have assigned a buy rating to the stock. Pfizer has an average rating of “Hold” and an average target price of $42.67.

In other Pfizer news, major shareholder Pfizer Inc purchased 55,556 shares of the business’s stock in a transaction on Monday, October 15th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $1,000,008.00. Following the acquisition, the insider now owns 21,976,484 shares of the company’s stock, valued at approximately $395,576,712. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. boosted its position in Pfizer by 1.5% during the 1st quarter. BlackRock Inc. now owns 459,530,944 shares of the biopharmaceutical company’s stock worth $16,308,754,000 after purchasing an additional 6,785,335 shares during the period. Capital World Investors boosted its position in Pfizer by 124.8% during the 3rd quarter. Capital World Investors now owns 85,032,960 shares of the biopharmaceutical company’s stock worth $3,747,403,000 after purchasing an additional 47,202,436 shares during the period. Bank of New York Mellon Corp boosted its position in Pfizer by 3.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 70,231,649 shares of the biopharmaceutical company’s stock worth $3,095,110,000 after purchasing an additional 2,497,736 shares during the period. Massachusetts Financial Services Co. MA boosted its position in Pfizer by 0.3% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 61,881,280 shares of the biopharmaceutical company’s stock worth $2,245,053,000 after purchasing an additional 160,730 shares during the period. Finally, Morgan Stanley boosted its position in Pfizer by 2.5% during the 2nd quarter. Morgan Stanley now owns 54,367,234 shares of the biopharmaceutical company’s stock worth $1,972,442,000 after purchasing an additional 1,345,528 shares during the period. 69.08% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Daily Political and is the property of of Daily Political. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.dailypolitical.com/2018/11/14/pfizer-inc-pfe-short-interest-down-7-5-in-october.html.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Recommended Story: Moving Average – How it Helps Investors in Stock Selection

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.